Table 1. Left part: description of free trough plasma concentrations (free C_min) deduced from imatinib and AGP levels available in samples from 36 GIST patients; right part: description of the samples from seven patients with exon 9 or wt KIT identified among 20 with known tumour KIT genotype.

	*All patients (wt, exon 9 and exon 11 KIT)*		*Exon 9 and wt KIT* patients**
RECIST response	n (blood samples)	Median free C_min and range (ng ml⁻¹)	n (blood samples)	Median free C_min and range (ng ml⁻¹)
Progressive disease	50	13.4 (3.8–22.9)	19	10.1 (6.1–17.4)
Stable disease	63	15.8 (4.5–39.3)	4	19.9 (13.7–20.2)
Partial response	72	13.3 (2.8–33.0)	2	20.5 (14.9–26.1)
Complete response	8	26.0 (25.0–27.0)	8	26.0 (25.0–27.0)

Abbreviations: AGP=α₁-acid glycoprotein; GIST=gastrointestinal stromal tumour; RECIST, response evaluation criteria in solid tumours.

Each patient provided between 1 and 12 samples over 3 years (median: 4 samples per patient), along with current RECIST response status.

Table 1. Left part: description of free trough plasma concentrations (free Cmin) deduced from imatinib and AGP levels available in samples from 36 GIST patients; right part: description of the samples from seven patients with exon 9 or wt KIT identified among 20 with known tumour KIT genotype.